CDKN2C/p18 INK4c Antibody (118.2): sc-9965

p18 INK4C Antibody (118.2) is a mouse monoclonal IgG2a kappa light chain antibody that detects p18 INK4C of mouse, rat, and human origin through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry (IHCP), and enzyme-linked immunosorbent assay (ELISA). p18 INK4C (118.2) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase, phycoerythrin, fluorescein isothiocyanate, and multiple Alexa Fluor® conjugates. p18 INK4C plays a crucial role in regulating the cell cycle by inhibiting cyclin-dependent kinases, specifically Cdk4 and Cdk6, which are essential for the transition from the G1 phase to the S phase of the cell cycle. This regulation is vital for maintaining proper cell proliferation and preventing uncontrolled cell growth, which can lead to tumorigenesis. p18 INK4C interacts predominantly with Cdk6 and, to a lesser extent, with Cdk4, thereby serving as a critical checkpoint in cell cycle control. p18 INK4C′s ability to inhibit cyclin D-Cdk6 kinase activity underscores its importance in tumor suppression, particularly in the context of cellular responses to growth factors and stress signals. The gene encoding p18 INK4C is located in a chromosomal region frequently altered in various cancers, highlighting its potential as a biomarker for tumor progression and a target for therapeutic intervention.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CDKN2C/p18 INK4c Antibody (118.2) References:

1. p18(INK4c) collaborates with other CDK-inhibitory proteins in the regenerating liver.  |  Luedde, T., et al. 2003. Hepatology. 37: 833-41. PMID: 12668976
2. p18(INK4c) expression in hepatocellular carcinoma.  |  Luedde, T., et al. 2005. Hepatology. 41: 405; author reply 406. PMID: 15660428
3. Deletion of p18(INK4c) aggravates cisplatin-induced acute kidney injury.  |  Wang, L., et al. 2014. Int J Mol Med. 33: 1621-6. PMID: 24714825
4. CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML.  |  Schmalzbauer, BS., et al. 2022. Cancers (Basel). 14: PMID: 35326705
5. G1 phase progression: cycling on cue.  |  Sherr, CJ. 1994. Cell. 79: 551-5. PMID: 7954821
6. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.  |  Hunter, T. and Pines, J. 1994. Cell. 79: 573-82. PMID: 7954824
7. Germline p16 mutations in familial melanoma.  |  Hussussian, CJ., et al. 1994. Nat Genet. 8: 15-21. PMID: 7987387
8. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.  |  Guan, KL., et al. 1994. Genes Dev. 8: 2939-52. PMID: 8001816
9. Rates of p16 (MTS1) mutations in primary tumors with 9p loss.  |  Cairns, P., et al. 1994. Science. 265: 415-7. PMID: 8023167
10. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.  |  Hannon, GJ. and Beach, D. 1994. Nature. 371: 257-61. PMID: 8078588
11. A cell cycle regulator potentially involved in genesis of many tumor types.  |  Kamb, A., et al. 1994. Science. 264: 436-40. PMID: 8153634
12. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.  |  Serrano, M., et al. 1993. Nature. 366: 704-7. PMID: 8259215

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CDKN2C/p18 INK4c Antibody (118.2) has 27 citations in a variety of scientific publications.

Primary antibodies like Anti-CDKN2C/p18 INK4c Antibody (118.2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CDKN2C/p18 INK4c Antibody (118.2) Specifications

Alternate Product Name: p18 INK4C

Product Clone Name: 118.2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids:

Epitope Target: p18 INK4C

Epitope Species: human

Product Reactivity/Detection: p18 INK4C

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 27 citations in various scientific publications

Available Conjugates/Forms for CDKN2C/p18 INK4c Antibody (118.2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin